Goodin DS and Bates D.Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler2009; 15: 1175-1182.
2.
Goodin DSDisease-modifying therapy in multiple sclerosis: update and clinical implications . Neurology2008; 71(24 Suppl 3): S8-13.
3.
Miller DH, Weinshenker BG, Filippi M., et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler2008; 14: 1157-1174.
4.
Kappos L., Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet2007; 370: 389-397.
5.
Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease . The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke2009; 40: 2276-2293.
6.
Chandratheva A., Mehta Z., Geraghty OC, Marquardt L., Rothwell PMPopulation-based study of risk and predictors of stroke in the first few hours after a TIA. Neurology2009; 72: 1941-1947.
7.
Kappos L., Freedman MS, Polman CH, et al. Long-term impact of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis. Lancet Neurology2009; (in press).
